Dry Eye Disease (DED)

Ophthalmology
5
Pipeline Programs
4
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Thea Pharma
Thea PharmaMA - Waltham
3 programs
1
T2769Phase 41 trial
CyclosporinN/A1 trial
T2769N/A1 trial
Active Trials
NCT07234318Not Yet RecruitingEst. Jun 2026
NCT07007702CompletedEst. Jun 2025
NCT06903741RecruitingEst. Jun 2026
Bausch + Lomb
Bausch + LombNJ - Bridgewater
3 programs
2
1
instillation of NOV03Phase 41 trial
NOV03Phase 31 trial
NOV03Phase 31 trial
Active Trials
NCT04139798Completed599Est. Mar 2021
NCT04140227Completed256Est. Jan 2022
NCT05723770Completed33Est. Dec 2023
BRIM Biotechnology
BRIM BiotechnologyTaiwan - Taipei
1 program
1
BRM421 Ophthalmic Solution, 0.03%Phase 21 trial
Active Trials
NCT07078955Not Yet RecruitingEst. Mar 2027
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
ShamN/A1 trial
Active Trials
NCT07332988Enrolling By InvitationEst. Aug 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Thea PharmaT2769
Bausch + Lombinstillation of NOV03
Bausch + LombNOV03
Bausch + LombNOV03
BRIM BiotechnologyBRM421 Ophthalmic Solution, 0.03%
Thea PharmaCyclosporin
T-TherapeuticsSham
Thea PharmaT2769

Clinical Trials (8)

Total enrollment: 888 patients across 8 trials

NCT06903741Thea PharmaT2769

New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Start: Oct 2025Est. completion: Jun 2026
Phase 4Recruiting
NCT05723770Bausch + Lombinstillation of NOV03

Effects of NOV03 on the Tear Film

Start: Aug 2023Est. completion: Dec 202333 patients
Phase 4Completed
NCT04140227Bausch + LombNOV03

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Start: Sep 2020Est. completion: Jan 2022256 patients
Phase 3Completed
NCT04139798Bausch + LombNOV03

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Start: Jul 2020Est. completion: Mar 2021599 patients
Phase 3Completed
NCT07078955BRIM BiotechnologyBRM421 Ophthalmic Solution, 0.03%

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

Start: Dec 2025Est. completion: Mar 2027
Phase 2Not Yet Recruiting
NCT07234318Thea PharmaCyclosporin

Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears

Start: Dec 2025Est. completion: Jun 2026
N/ANot Yet Recruiting
NCT07332988T-TherapeuticsSham

Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients With Graves Disease

Start: Aug 2025Est. completion: Aug 2026
N/AEnrolling By Invitation
NCT07007702Thea PharmaT2769

Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease

Start: Jan 2025Est. completion: Jun 2025
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 888 patients
4 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)